Shares of OrthoPediatrics (KIDS) have gained 1% over the past four weeks to close the last trading session at $16.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $24.89 indicates a potential upside of 51.1%.The mean estimate comprises nine short-term price targets with a standard deviation of $4.4. While the lowest estimate of $20.00 indicates a 21.4% increase from the curre ...

POTTERY BARN KIDS AND POTTERY BARN TEEN LAUNCH EXCLUSIVE COLLABORATION WITH HILL HOUSE HOME Share POTTERY BARN KIDS AND POTTERY BARN TEEN LAUNCH EXCLUSIVE COLLABORATION WITH HILL HOUSE HOME Mar 24, 2026 8:55 AM Eastern Daylight Time New Collections Bring Hill House Home's Signature Aesthetic to Baby, Kids, Teen and Dorm Spaces Hill House Home x Pottery Barn Kids SAN FRANCISCO--(BUSINESS WIRE)--Pottery Barn Kids and Pottery Barn Teen, portfolio brands of Williams-Sonoma, Inc. (NYSE: WSM), the world's largest ...

OrthoPediatrics Conference Call Summary Company Overview - **Company**: OrthoPediatrics (NasdaqGM: KIDS) - **Industry**: Pediatric orthopedic medical devices Key Points and Arguments New Product Cycle and Super Cycle - OrthoPediatrics is entering a "Super Cycle" with a series of new product launches that will significantly impact financial performance in the coming years [2][3] - The company has expanded its product offerings from 17 systems at the time of going public in 2017 to 87 systems today, including both surgical and bracing options [4][5] Product Innovations - **Trauma and Deformity (T&D)**: This segment accounts for approximately 70% of sales. Recent launches include: - Pediatric nailing platform with femur and tibia products, with a retrograde product in development [7][8] - 3P pediatric plating platform, including the 3P Hip launched in 2025 and additional systems expected in 2026-2028 [19] - **Scoliosis Products**: - Launch of VertiGlide, which allows for growth while correcting curvature, expected to ramp up in 2026 [20][22] - eLLi, a growing spine rod that expands mechanically, with first human trials planned for fall 2026 [23] - **Enabling Technology**: - Playbook, a device for OR efficiency, and iotaMotion, a small robot for cochlear implants, are also in development [37] - **Bracing Products**: OPSB specialty bracing business is expected to grow over 20% annually, with plans to expand clinic locations [50][51] Financial Performance and Cash Flow - Expected free cash flow to be positive in 2026, driven by: - Increased EBITDA from $15 million in 2025 to $25 million in 2026 [45] - More efficient product sets and improved selling prices [46] - Focus on working capital management, including accounts receivable and inventory improvements [46] Competitive Landscape - The company is experiencing reduced competition due to larger companies pulling products from the market, particularly in the trauma and deformity segment, due to EU MDR regulations [62][68] - OrthoPediatrics is positioned to fill the gap left by competitors, with new and improved solutions ready for launch [69] Sales Force and Talent Acquisition - The company has no issues attracting talent, particularly from other specialties, to support its pediatric focus [61] - The competitive landscape has created opportunities for OrthoPediatrics to recruit skilled sales personnel [60] Future Growth and Market Position - OrthoPediatrics aims to serve all segments of pediatric orthopedics, with potential expansion beyond orthopedic products [71] - The company is not currently viewed as a takeover candidate, as it seeks to maintain its unique culture and operational focus [70] Additional Important Information - The 7D navigation device for scoliosis procedures is a significant innovation, offering zero radiation navigation, which is highly favored by surgeons [55][56] - The company is exploring various sales models for its products, including direct sales, consignment, and leasing options [56] This summary encapsulates the key insights from the OrthoPediatrics conference call, highlighting the company's strategic direction, product innovations, financial outlook, and competitive positioning in the pediatric orthopedic market.

Financial Performance and Taxation - As of December 31, 2025, the company had federal, state, and foreign net operating loss carryforwards (NOLs) of $172.2 million, $103.7 million, and $37.8 million, respectively, with federal NOLs beginning to expire in 2028[191]. - The company faces an estimated annual limitation of $9.7 million on the use of pre-change NOLs due to ownership changes, which could increase tax obligations and negatively impact future operating results[193]. - The company’s effective tax rate may fluctuate due to various factors, including changes in tax laws and profitability across jurisdictions, potentially leading to tax obligations exceeding accrued amounts[190]. Competition and Market Environment - The company operates in a highly competitive environment with significant competitors including Johnson & Johnson MedTech, Medtronic, and Smith & Nephew, which may affect market share and pricing strategies[202]. - The company’s ability to commercialize new products and enhance existing offerings is critical for maintaining market share in the pediatric orthopedic market[196]. - The proliferation of physician-owned distributorships (PODs) may increase pricing pressure and affect the ability to sell products to affiliated physicians[243]. Regulatory Compliance and Risks - The company may face regulatory scrutiny regarding the provision of loaned instrument sets to customers, which could implicate federal and state fraud and abuse laws[209]. - Compliance with various U.S. and international laws, including the FCPA, poses risks that could result in substantial fines and operational curtailments[261]. - The company must comply with various healthcare fraud and abuse laws, which could result in substantial penalties if violated[316]. - Non-compliance with federal and state regulations could lead to product recalls or production termination, significantly impacting supply[298]. - The FDA may change its clearance and approval policies, which could delay future product approvals and increase compliance costs[289]. Product Development and Approval - ApiFix Mid-C System received FDA approval under the Humanitarian Device Exemption (HDE) regulation in August 2019, requiring annual reports to maintain exemption status[285]. - The company has obtained 510(k) premarket clearance from the FDA for all products requiring such clearance, but future modifications may necessitate new clearances or PMA approvals[288]. - The Medical Devices Regulation (MDR) was enacted in May 2017, with additional reporting requirements and a certification received on December 10, 2025, impacting product sales in the EEA[292]. Operational Challenges - The company must maintain significant levels of inventory for implant and instrument sets, which could lead to inventory impairment charges if portions become obsolete[208]. - The company faces challenges in identifying and integrating suitable acquisitions or strategic relationships, which could disrupt ongoing operations and require significant resources[212]. - The company faces risks associated with attracting and retaining skilled personnel, which is critical for supporting commercial and R&D operations[252]. Financial Structure and Shareholder Impact - The company may issue shares to finance acquisitions, which could dilute existing shareholders' ownership and may not be feasible if stock prices are low or volatile[214]. - The conversion of Convertible Notes may dilute existing stockholders' ownership interests and could depress the price of common stock[246]. - As of December 31, 2025, the company’s principal stockholders and management owned approximately 32.6% of the outstanding common stock, allowing them significant control over corporate actions[371]. Revenue and Sales Trends - Revenue increased from $204.7 million in 2024 to $236.3 million in 2025, reflecting a growth rate of approximately 15.5%[248]. - Approximately 21% of revenue for the years ended December 31, 2025 and 2024 was attributable to international customers, down from 25% in 2023[254]. - Seasonal fluctuations affect revenue, with higher sales typically occurring in summer months and holiday periods due to increased pediatric surgeries[225]. Intellectual Property and Legal Risks - The company’s ability to enforce patent rights may be challenged, which could harm its competitive position and require significant expenses to defend[340]. - The company faces significant risks related to intellectual property infringement, which could lead to substantial legal costs and impact product sales[348]. - Legal proceedings related to intellectual property could divert management's attention and resources, potentially harming business operations[357]. Environmental and Operational Risks - The company does not carry insurance specifically for environmental claims related to hazardous materials, but reserves funds for potential claims[324]. - Climate change and related regulations may lead to increased operational costs and affect employee productivity due to natural disasters[263][264]. - Natural disasters and other uncontrollable events could disrupt operations and delay product shipments, impacting overall business performance[280]. Technology and Cybersecurity - The company relies heavily on information technology systems, and disruptions could adversely affect operations and financial results[270][272]. - Increased cybersecurity threats pose risks to data integrity and could result in significant recovery costs and reputational damage[273][274]. Future Outlook and Strategic Plans - The company plans to grow through acquisitions or investments in complementary businesses, products, or technologies, which could increase debt and operational risks if not managed properly[210]. - The company initiated a restructuring plan in 2024 aimed at improving operational efficiency and reducing costs, which includes workforce reductions and site reductions[253].

Summary of OrthoPediatrics Conference Call Company Overview - **Company**: OrthoPediatrics - **Industry**: Pediatric Orthopedics - **Key Executives Present**: David Bailey (President and CEO), Joe Hauser (President of Trauma and Deformity, OPSB) Key Financial Highlights - **Q4 Performance**: Strong demand for Trauma and Deformity (T&D) implants in the U.S. and internationally, with significant growth in scoliosis products driven by the deployment of 7D technology and early procedures with VerteGlide [4][10] - **Free Cash Flow**: Achieved $10 million in free cash flow for Q4, marking the first quarter of positive cash flow [5] - **2026 Guidance**: Projected top-line growth of 11%-13%, with an adjusted EBITDA of $25 million and at least break-even cash flow [8] Business Segments Trauma and Deformity (T&D) - **Market Position**: T&D is the foundational product line for OrthoPediatrics, with over 40 systems in major children's hospitals across the U.S. [30] - **Competitive Landscape**: Limited competition focused solely on pediatrics, allowing for easier adoption of new products [32] - **New Product Launches**: Anticipated launches include the 3P Hip System and a Small-Mini System, with a goal of at least one major system launch annually [65][66] OrthoPediatrics Specialty Bracing (OPSB) - **Market Opportunity**: Estimated total addressable market (TAM) of $500 million, with current penetration around 10% [90] - **Growth Strategy**: Focus on expanding into new geographical markets and leveraging existing relationships with hospitals [92][94] - **Profitability**: OPSB has lower gross margins but higher contribution margins due to lower selling costs and no capital deployment [99] Scoliosis - **Market Share**: Represents about 25% of global revenue, with less than 20% market share in children's hospitals [111] - **Competitive Advantage**: Focus on early onset scoliosis with limited competition and investment in technology development [118] - **Key Products**: VerteGlide and RESPONSE ribbon Pelvic device are part of a comprehensive portfolio aimed at addressing significant clinical needs [121] Strategic Insights - **Regulatory Approvals**: Recent EU MDR approvals are expected to enhance international growth, particularly in the scoliosis and trauma markets [14] - **Market Dynamics**: Competitors are withdrawing from pediatric products due to regulatory costs, providing OrthoPediatrics with a unique opportunity to capture market share [33][37] - **Long-Term Growth**: The company is positioned for sustained growth with a focus on innovative product development and expanding its market presence [125] Conclusion OrthoPediatrics is strategically positioned in the pediatric orthopedic market with strong financial performance, a robust product pipeline, and significant growth opportunities in both existing and new markets. The company's focus on specialized pediatric products and its unique market position differentiate it from broader orthopedic competitors.

Core Viewpoint - OrthoPediatrics (KIDS) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system highlights the strong correlation between changes in earnings estimates and near-term stock price movements, making it a valuable tool for investors [2][4]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Business Improvement Indicators - The upgrade in OrthoPediatrics' rating reflects an improvement in the company's underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - Over the past three months, the Zacks Consensus Estimate for OrthoPediatrics has increased by 7.8%, indicating a positive trend in earnings estimates [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, positioning OrthoPediatrics favorably within this group due to its earnings estimate revisions [9][10].

Core Viewpoint - OrthoPediatrics (KIDS) has shown a significant price increase of 11.2% over the past four weeks, with a mean price target of $25.5 indicating a potential upside of 32.7% from its current price of $19.22 [1] Price Targets and Analyst Consensus - The average price target consists of eight estimates ranging from a low of $22.00 to a high of $34.00, with a standard deviation of $4.28, suggesting a variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 14.5%, while the highest suggests a 76.9% upside [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Upside Potential - Analysts have shown increasing optimism about KIDS' earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 7%, with one estimate moving higher and no negative revisions [12] - KIDS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of potential gains, the direction implied by these targets appears to be a useful guide for further research [14]

www.OrthoPediatrics.com Disclaimer Forward-Looking Statements 2026 Investor Presentation All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "ma ...

Core Insights - OrthoPediatrics reported revenue of $61.61 million for the quarter ended December 2025, marking a year-over-year increase of 17% and exceeding the Zacks Consensus Estimate by 4.05% [1] - The company’s EPS for the same period was -$0.26, an improvement from -$0.29 a year ago, with a surprise of 29.73% compared to the consensus estimate of -$0.37 [1] Revenue Performance - Product sales in the Trauma and deformity category reached $42.64 million, slightly below the estimated $43.45 million, but still reflecting a year-over-year increase of 17.1% [4] - Sales in the Sports medicine/other category were reported at $1.37 million, significantly surpassing the average estimate of $0.68 million, representing a remarkable year-over-year growth of 118.5% [4] - Scoliosis product sales amounted to $17.6 million, exceeding the estimated $15.17 million, with a year-over-year increase of 12.6% [4] Stock Performance - Over the past month, OrthoPediatrics shares have returned -3.5%, contrasting with the Zacks S&P 500 composite's increase of +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported a revenue of $61.6 million, a 17% increase compared to Q4 2024 [22] - Full year 2025 revenue growth was 15%, with adjusted EBITDA increasing by nearly 75% [8] - The company generated $10 million in free cash flow in Q4 2025, marking its first positive free cash flow quarter in history [7][28] - The gross profit margin improved to 73% in Q4 2025, up from 68% in Q4 2024 [25] Business Line Data and Key Metrics Changes - The Trauma and Deformity (T&D) business grew by 17% in Q4 2025, driven by strong sales of flagship products [11] - Scoliosis revenue increased by 13% in Q4 2025, supported by international implant growth [24] - The Specialty Bracing (OPSB) business continued to be a strategic growth catalyst, with strong same-store sales growth and successful new product launches [14] Market Data and Key Metrics Changes - U.S. revenue was $48.6 million in Q4 2025, a 13% increase, representing 79% of total revenue [23] - International revenue reached $13.0 million, a 33% increase, accounting for 21% of total revenue [23] - The company experienced strong demand in direct markets in the EU and Australia, with a rebound in Latin America [19] Company Strategy and Development Direction - The company aims to help 1 million children annually and is focused on expanding its product portfolio and market presence [9] - A multi-year product innovation cycle is underway, with significant product launches planned [10] - The company is exploring opportunities in pediatric subspecialties beyond orthopedics, including cardiovascular technologies [44][73] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining revenue growth and achieving cash flow breakeven in 2026 [8][28] - The company anticipates continued share gains and improved EBITDA margins driven by new product launches [10][11] - Management highlighted the importance of the EU MDR approvals for expanding product offerings in Europe [20][88] Other Important Information - The company recorded a GAAP net loss per share of $0.43 in Q4 2025, an improvement from $0.69 in the prior year [26] - Non-GAAP net loss per share was $0.30, compared to $0.29 in the same period last year [27] - The company is committed to maintaining a strong R&D pipeline, with several innovative products expected to launch in the coming years [80] Q&A Session Summary Question: Insights on Scoliosis performance and competitive pressure - Management noted strong performance in the Scoliosis segment, driven by the VerteGlide system and new product launches, with expectations for continued growth [33][34] Question: Outlook on margin progression - Management indicated that gross margins are expected to remain around 73% in 2026, with adjusted EBITDA projected to increase significantly [36] Question: Exploration of options to increase shareholder value - Management emphasized the potential for expanding the commercial footprint into other pediatric subspecialties, leveraging existing infrastructure [42][44] Question: Updates on 7D placements and strategy - Management reported normal growth in 7D placements, with optimism for 2026 based on strong performance in existing accounts [55] Question: Impact of new product launches on guidance - Management stated that while there is significant interest in new products, minimal revenue from these launches is included in the 2026 guidance [57] Question: Pricing and margin impact from new products - Management confirmed that new technologies are commanding higher premiums, which will positively impact profitability over time [87] Question: EU MDR strategy and market penetration - Management highlighted the importance of having a full range of product sizes approved in Europe, which will facilitate surgeon conversions and drive growth [88] Question: Cardiovascular business margin profile - Management indicated that the gross margin profile for the cardiovascular business is expected to be higher than the current implant business, which is encouraging for future profitability [90]